Physics Bucharest 2017

TARGIT clinical trials • Phase 3 RCT compared single 20Gy TARGIT with whole breast irradiation

• Over 3,500 patients recruited from 33 centres

• Entry if > 45 years and solitary cancer < 3.5cm diameter

• Additional EBRT given in 1 in 5 if histology more adverse (risk stratified approach)

• Recurrence 3.3% TARGIT vs. 1.3% EBRT

• Controversy about statistical analysis and interpretation

Vaidya et al. Lancet (2014) 383: 603-13